CSL's total inventories for the quarter that ended in Dec. 2025 was €5,611 Mil. CSL's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was €5,608 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. CSL's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was €-20.92.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
CSL's Days Inventory for the
six
months ended in Dec. 2025 was 309.69.
Inventory Turnover measures how fast the company turns over its inventory within a year.
CSL's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.59.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CSL's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.81.
CSL (HAM:CSJ) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
CSL's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CSL's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
CSL Total Inventories Related Terms
CSL Total Inventories Historical Data
* Premium members only.
The historical data trend for CSL's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
CSL (HAM:CSJ) has a Total Inventories of €5,611 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for CSL and its competitors.
Is CSL's Total Inventories too high?
CSL's current Total Inventories is €5,611 Mil. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Total Inventories compare to VRTX and REGN?
CSL's Total Inventories of €5,611 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for CSL and its competitors. CSL's current Total Inventories is €5,611 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €170.71, compared to a current price of €68.23 — trading 60% below its estimated fair value. The current Total Inventories is €5,611 Mil. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For CSL (HAM:CSJ), the current Total Inventories is €5,611 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (HAM:CSJ) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of €68.23 is trading 60% below its estimated GF Value™ of €170.71.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for HAM:CSJ:
Total Inventories: €5,611 Mil
GF Value™: €170.71 vs. price of €68.23 (60% below fair value)
No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for HAM:CSJ
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:CSJ has been successfully added to your 
